<DOC>
	<DOCNO>NCT02220985</DOCNO>
	<brief_summary>This phase II trial study well selective T cell depletion work prevent graft-versus-host disease ( GVHD ) patient acute lymphocytic leukemia , acute myeloid leukemia , chronic myelogenous leukemia undergo donor peripheral blood stem cell transplant . Giving chemotherapy total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Removing subset T cell donor cell transplant may stop happening .</brief_summary>
	<brief_title>Selective Depletion CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related Unrelated Donors Preventing GVHD</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate probability develop chronic GHVD among patient receive naive T cell ( TN ) -depleted peripheral blood stem cell transplant ( PBSCT ) follow group : ) Arm A : patient receive TN-depleted peripheral blood stem cell ( PBSC ) human leukocyte antigen ( HLA ) match related donor ( MRD ) follow high-intensity myeloablative conditioning ( total body irradiation [ TBI ] 1320 cGy , thiotepa , fludarabine phosphate [ fludarabine ] ) pharmacological immunosuppression tacrolimus methotrexate ; b ) Arm B : patient receive TN-depleted PBSC MRD follow lower-intensity myeloablative conditioning ( TBI 400 cGy , thiotepa , fludarabine cyclophosphamide ) pharmacological immunosuppression tacrolimus mycophenolate mofetil ( MMF ) ; c ) Arm C : patient receive TN-depleted PBSC HLA-matched unrelated donor ( MUD ) follow high-intensity myeloablative conditioning ( TBI 1320 cGy , thiotepa , fludarabine ) pharmacological immunosuppression tacrolimus methotrexate ; ) Arm D : patient receive TN-depleted PBSC MUD follow lower-intensity myeloablative conditioning ( TBI 400 cGy , thiotepa , fludarabine cyclophosphamide ) pharmacological immunosuppression tacrolimus MMF . II . To estimate probability acute ( ) GVHD grade II-IV follow TN-depleted ( TND ) PBSCT tacrolimus methotrexate ( Arm A ) MMF ( Arm B ) GVHD prophylaxis MRD recipient . III . Estimate rate aGVHD grade II-IV follow TND PBSCT tacrolimus methotrexate ( Arm C ) MMF ( Arm D ) prophylaxis recipient MUD hematopoietic cell transplantation ( HCT ) . IV . Estimate probability graft failure recipient CD45RA+ TN-depleted PBSCT tacrolimus methotrexate ( MTX ) MMF GVHD prophylaxis . SECONDARY OBJECTIVES : I . Estimate probability transplant-related mortality day 100 . II . Estimate probability relapse . III . Evaluate immune reconstitution pathogen-specific immune reconstitution . OUTLINE : Patients assign 1 4 treatment arm . CONDITIONING : ARMS A AND C ( high-intensity myeloablative conditioning ) : Patients undergo total body irradiation twice daily ( BID ) day -10 -7 . Patients also receive thiotepa intravenously ( IV ) 4 hour day -6 -5 fludarabine phosphate IV 30 minute day -6 -2 . ARMS B AND D ( lower-intensity myeloablative conditioning ) : Patients receive cyclophosphamide IV 1 hour day -6 , fludarabine phosphate IV 30 minute day -6 -2 , thiotepa IV 4 hour day -5 -4 . Patients also undergo total body irradiation daily ( QD ) day -2 -1 . TRANSPLANT : In arm , patient undergo allogeneic HSCT granulocyte colony-stimulating factor ( GCSF ) -mobilized CD34-enriched PBSC CD45RA-depleted cell day 0 . GVHD PROPHYLAXIS : ARMS A AND C : Beginning day -1 , patient receive tacrolimus IV 22-24 hour orally ( PO ) ( BID give PO ) 50 day taper absence GVHD . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . ARMS B AND D : Beginning day -1 , patient receive tacrolimus IV 22-24 hour PO ( BID give PO ) 50 day mycophenolate mofetil IV PO every 8 hour day -3 approximately day 30 , without taper discretion treat physician . Mycophenolate mofetil continue resumed day 30 donor chimerism low , discussion principal investigator . After completion study treatment , patient follow 80-100 day , 360 day , yearly 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients consider appropriate candidate allogeneic hematopoietic stem cell transplantation one follow diagnosis : Acute lymphocytic leukemia first subsequent remission Acute myeloid leukemia first subsequent remission Acute lymphocytic leukemia relapse primary refractory disease circulate blast count 10,000/mm^3 ( Arms A C ) Acute myeloid leukemia relapse primary refractory disease circulate blast count 10,000/mm^3 ( Arms A C ) Refractory anemia excess blast ( RAEB1 RAEB2 ) ( patient receive previous induction chemotherapy within 60 day ) Chronic myelogenous leukemia history accelerate phase blast crisis ( patient receive least one course induction chemotherapy ) Other acute leukemia relate neoplasm ( include limit 'biphenotypic ' , 'undifferentiated ' 'ambiguous lineage ' acute leukemia , blastic plasmacytoid dendritic cell neoplasm lymphoblastic lymphoma ) Patients 049 year old enrol Arm A C ( highintensity ) Patients 5060 year old enrol Arm B D ( low intensity ) ; patient eligible Arms B D also include receive previous allogeneic HCT , comorbid condition render unsuitable highdose conditioning , determine consultation principal investigator Patient HLAmatched ( HLAA , B , C , DR beta 1 [ DRB1 ] molecularly match ) unrelated donor relate donor capable donate PBSC DONOR INCLUSION : HLAmatched relate donor &gt; = 18 year capable willing donate PBSC ( Arms A B ) HLAmatched unrelated donor ( HLAA , B , C , DRB1 match base highresolution type ) capable willing donate PBSC ( Arms C D ) Patients central nervous system ( CNS ) involvement refractory intrathecal chemotherapy and/or standard cranialspinal radiation Patients experimental protocols prevention acute GVHD Patient weight &gt; = 100 kg ; patient &gt; = 70 kg MUDs must discuss principal investigator Patients human immunodeficiency virus positive ( HIV+ ) Patients uncontrolled infection myeloablative HCT consider contraindicate consult infectious disease physician ( upper respiratory tract viral infection constitute uncontrolled infection context ) Patients organ dysfunction ARM A OR C EXCLUSION : Creatinine &gt; 1.5 mg/dl present time ; patient know history creatinine &gt; 1.5 mg/dl must current estimate creatinine clearance &gt; 40 ml/min Cardiac ejection fraction &lt; 45 % Diffusing capacity lung carbon monoxide ( DLCO ) correct &lt; 60 % Liver function abnormality ; patient liver function test ( LFTs ) ( include total bilirubin , aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) &gt; = twice upper limit normal evaluate gastrointestinal ( GI ) physician ; unless clear precipitate factor ( azole , methotrexate , Bactrim another drug ) ; GI physician considers HCT highintensity arm protocol contraindicate patient patient may consider treatment low intensity arm protocol exclude protocol ; patient Gilbert 's syndrome know liver function abnormality patient reversible drugrelated transaminitis necessarily require GI consultation may include highintensity arm protocol ARM B OR D EXCLUSION : Creatinine &gt; 2.0 mg/dl present time ; patient know history creatinine &gt; 1.5 mg/dl must current estimate creatinine clearance &gt; 40 ml/min Cardiac ejection fraction &lt; 35 % DLCO correct &lt; 50 % ; patient DLCO 5060 % must also partial pressure oxygen ( pO2 ) &gt; 80 mmHg Liver function abnormality ; patient LFTs &gt; = twice upper limit normal evaluate GI physician ; unless clear precipitate factor ( azole , methotrexate , Bactrim another drug ) ; patient fulminant liver failure , cirrhosis evidence portal hypertension bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , correctable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease exclude Patients exclude Arms A C receive previous myeloablative transplant ; patient receive prior HCT least 6 month prior may consider inclusion Arms B D discussion principal investigator ( PI ) Patients life expectancy &lt; 3 month coexist disease leukemia RAEB Patients pregnant breastfeed Fertile patient child bearing age unwilling use contraception 12 month posttransplant Patients significant medical condition would make unsuitable transplant Patients know hypersensitivity tacrolimus , methotrexate ( Arm A C ) MMF ( Arm B D ) DONOR EXCLUSION : Donors HIV1 , HIV2 , human Tlymphotropic virus ( HTLV ) 1 , HTLV2 seropositive active hepatitis B hepatitis C virus infection Donors fail eligibility requirement donation cell tissue donation Human Cell Tissue Products ( HCT/P ) exclude unless use cell complies urgent medical need allogeneic use firstdegree seconddegree relative Unrelated donor donate outside United States America ( USA )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>